Platelet Amyloid Precursor Protein Abnormalities in Mild Cognitive Impairment Predict Conversion to Dementia of Alzheimer Type A 2-Year Follow-up Study

Archives of Neurology

Volumn 60, Issue 12, 2003, Pages 1740-1744

  Borroni, Barbara ^a   Colciaghi, Francesca ^b   Caltagirone, Carlo ^c   Rozzini, Luca ^a   Broglio, Laura ^a   Cattabeni, Flaminio ^b   Di Luca, Monica ^b   Padovani, Alessandro ^a,d  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; EVALUATION; FEMALE; FOLLOW UP; HUMAN; MALE; MEMORY DISORDER; NEUROPSYCHOLOGICAL TEST; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; RISK FACTOR; SCORING SYSTEM; THROMBOCYTE ANOMALY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; BLOOD PLATELETS; COGNITION DISORDERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PROGNOSIS; RISK FACTORS;

EID: 0348015821     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.60.12.1740     Document Type: Article

References (34)

1. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303-308.
2. Tierney MC, Szalai JP, Snow WG, et al. Prediction of probable Alzheimer's disease in memory-impaired patients: a prospective longitudinal study. Neurology. 1996;46:661-665.
3. Ritchie K, Touchon J. Mild cognitive impairment: conceptual basis and current nosological status. Lancet. 2000;355:225-228.
4. Petersen RC, Stevens JC; Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1133-1142.
5. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58:397-405.
6. Bozoki A, Giordani B, Heidebrink JL, et al. Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. Arch Neurol. 2001;58:411-416.
7. Hogan DB, McKeith IG. Of MCI and dementia: improving diagnosis and treatment. Neurology. 2001;56:1131-1132.
8. Mehta PD, Pirttila T, Mehta SP, et al. Plasma and cerebrospinal fluid levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 2000;57:100-105.
9. Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001;58:373-379.
10. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid tau and β-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol. 2002;59:1729-1734.
11. Buerger K, Teipel SJ, Zinkowski R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002;59:627-629.
12. Bush AI, Martins RN, Rumble B, et al. The amyloid precursor protein of Alzheimer's disease is released by human platelets. J Biol Chem. 1990;265:15977-15983.
13. Rosenberg RN, Baskin F, Fosmire JA, et al. Altered amyloid protein processing in platelets of patients with Alzheimer disease. Arch Neurol. 1997;54:139-144.
14. Baskin F, Rosenberg RN, Iyer L, et al. Platelet APP isoform ratios correlate with declining cognition in AD. Neurology. 2000;54:1907-1909.
15. Padovani A, Pastorino L, Borroni B, et al. Amyloid precursor protein in platelets: a peripheral marker for the diagnosis of sporadic AD. Neurology. 2001;57:2243-2248.
16. Padovani A, Borroni B, Colciaghi F, et al. Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. Arch Neurol. 2002;59:71-75.
17. Burke WJ, Miller JP, Rubin EH, et al. Reliability of the Washington University Clinical Dementia Rating. Arch Neurol. 1988;45:31-32.
18. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
19. Rosen WG, Mohs RC, Davis KL, et al. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
20. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-2314.
21. Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. In: Brink TL, ed. Clinical Gerontology: A Guide to Assessment and Intervention. Binghamton, NY: Haworth Press Inc; 1986:165-173.
22. Gjerris A, Bech P, Bojholm S, et al. The Hamilton Anxiety Scale: evaluation of homogeneity and inter-observer reliability in patients with depressive disorders. J Affect Disord. 1983;5:163-170.
23. Lawton MP, Broody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179-186.
24. Sheikh K, Smith DS, Meade TW, Goldenberg E, Brennan PJ, Kinsella G. Repeatability and validity of a modified activities of daily living (ADL) index in studies of chronic disability. Int Rehabil Med. 1979;1:51-58.
25. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985-1992.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
27. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1994;57:416-418.
28. McKeith G, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113-1124.
29. Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology. 1991;41:1006-1009.
30. Crystal H, Dickson D, Fuld P, et al. Clinico-pathological studies in dementia: non-demented subjects with pathologically confirmed Alzheimer's disease. Neurology. 1988;38:1682-1687.
31. Blass JP. Alzheimer's disease and Alzheimer's dementia: distinct but overlapping entities. Neurobiol Aging. 2002;23:1077-1084.
32. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review): report of the Quality Standards Sub-committee of the American Academy of Neurology. Neurology. 2001;56:1143-1153.
33. 123]I-iodoamphetamine SPECT in mild cognitive impairment: implications for a novel predictor of Alzheimer's disease. Am J Psychiatry. 2002;159:474-476.
34. Growdon JH. Incorporating biomarkers into clinical drug trials in Alzheimer's disease. J Alzheimers Dis. 2001;3:287-292.